Lundbeck Archives

News and Trends 22 Apr 2022

European Biotech Investors Brace for Volatility in 2022

After gathering huge investment funds in 2021, European biotech investors took a breather in the first quarter of 2022, with the plan to steadily fund private biotechs amid a tumultuous public market. The last two years have seen a record-breaking amount of money flowing to biotech investors, with almost €10B reaching European life science funders […]

April 22, 2022 - 4 minutesmins - By Jonathan Smith

Interview 20 Nov 2018

Why Denmark Is a Strong Player in Europe’s Biotech Industry

Denmark is a rapidly growing hotspot for biotech. During the BIO-Europe conference in Copenhagen, I talked to Mette Kirstine Agger, Managing Partner at the life sciences investor Lundbeckfonden Ventures, to learn more about how the industry is evolving in Europe and Denmark. The US has traditionally been the leader in biotech, but that seems to […]

November 20, 2018 - 4 minutesmins - By Clara Rodríguez Fernández

lundbeck prexton therapeutics acquisition parkinsons

News and Trends 16 Mar 2018

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if the Swiss company’s Parkinson’s treatment proves successful. Danish pharma Lundbeck has decided to boost its pipeline with the acquisition of Prexton Therapeutics. The deal grants Lundbeck with global rights to foliglurax, a drug to reduce the “off” time periods when Parkinson’s motor […]

March 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Sep 2017

Belgian Biotech Teams Up With Lundbeck to Collaborate on Drug Discovery

Confo and Lundbeck have joined forces to push through drug discovery against a tough-to-target protein using Confo’s special technology. Confo Therapeutics develops small antibody fragments, ‘Confobodies’, that stabilize G-protein coupled receptors (GPCRs). Although Lundbeck has the exclusive license to commercialize compounds from the collaboration, Confo would receive up to €5M in technology fees, plus milestone payments and royalties depending on […]

September 26, 2017 - 2 minutesmins - By Alex Dale

More News! 21 Jun 2017

Swedish IPO raises €51M for Biomaterials to Repair Bone

Bonesupport has gone public in the Swedish stock market to push its pipeline and increase sales of biomaterials to regenerate bone tissue. Bonesupport is a company based in Lund, Sweden, that develops biomaterials to improve and speed up the repair of bones. The firm IPO’d today on the Nasdaq Stockholm, raising an impressive €51M with the participation […]

June 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 30 Jan 2017

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small size and high solubility. The company has now received a milestone payment from Danish pharma Lundbeck for the development of the technology as a delivery […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Aug 2015

Lundbeck dismisses 1,000 employees to stay competitive

Lundbeck’s new CEO Kåre Schultz completely restructures the company to regain profitability. About 1/6th of the company’s employees will have to leave for that reason. In May, former president and COO of Novo Nordisk Kåre Schultz became the new president and CEO of Lundbeck. The Danish drugmaker was struggling at that time because the patent of its blockbuster […]

August 20, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Lundbeck

European Biotech Investors Brace for Volatility in 2022

Why Denmark Is a Strong Player in Europe’s Biotech Industry

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Belgian Biotech Teams Up With Lundbeck to Collaborate on Drug Discovery

Swedish IPO raises €51M for Biomaterials to Repair Bone

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Lundbeck dismisses 1,000 employees to stay competitive

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!